Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRSP vs ACLX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRSP Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–4 Matrix Metrics)

CRSP Overall Winner 6-Pillar Tally: CRSP 4 – 1 ACLX (1 Tie) Matrix Metrics: CRSP 5 – 4 ACLX

As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) is the stronger overall head-to-head candidate over Arcellx, Inc. (ACLX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRSP carries a Unified Composite Score of 48.6/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin), whereas ACLX carries 61.7/100 (BUY) at $115.07 (61.7x Forward P/E, -3850.2% operating margin).

  • Composite vs. Pillar Nuance: While ACLX currently prints a higher short-term Unified Composite Score (61.7/100 BUY vs. CRSP 48.6/100 HOLD), CRSP captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-2058.6% vs. -3850.2% operating margin) and revenue trajectory (+1325.1% vs. -89.2% YoY).
  • Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile ACLX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRSP vs ACLX
CRSP NASDAQ Head-to-Head Winner
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $48.88 · SMA50: $51.80
ACLX NASDAQ
Arcellx, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$115.07
+0.03% 1D
Market Cap $6.7B
TTM Revenue $22M
Forward P/E 61.7x
Beta / 30D Vol -0.83β · 1% Vol
Unified Composite Score
61.7 / 100 BUY
Tech 40.0 Fund 50.0 Flow 60.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (20.2% over 20 days), RSI 79
RSI-14: 79.4 · SMA20: $114.90 · SMA50: $109.88

6-Pillar Scorecard Institutional Category Breakdown (CRSP 4 – 1 ACLX)

Columns: Metric · CRSP · ACLX
1. Valuation Multiples CRSP
Forward P/E 23.4x 61.7x
Trailing P/E 23.4x 61.7x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CRSP
Revenue Growth (YoY) +1325.1% -89.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $25M $22M
Market Cap $4.1B $6.7B
3. Profitability & Quality CRSP
Gross Margin N/A N/A
Operating Margin -2058.6% -3850.2%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -25.6% -53.4%
4. Balance Sheet & Cash Flow CRSP
Cash Generation (TTM) -$378M -$246M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $588M Net Debt (0.47x D/E) $6.95 Book/Sh · -53.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACLX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 97.8% (52nd %ile) 1.5% (1st %ile)
Put/Call OI Skew 0.65x (Call-Skewed) 9.73x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRSP (5) vs ACLX (4)
Institutional Metric CRSP ACLX Criterion Row Edge
Market Capitalization
Scale
$4.1B $6.7B Larger Scale ACLX
Trailing P/E Ratio
Valuation
23.4x 61.7x Lower Multiple CRSP
Forward P/E Ratio
Valuation
23.4x 61.7x Lower Multiple CRSP
Revenue Growth (YoY)
Growth
+1325.1% -89.2% Higher Growth CRSP
Operating Margin (TTM)
Profitability
-2058.6% -3850.2% Higher Margin CRSP
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-25.6% -53.4% Higher ROE CRSP
52-Week Range Position
Momentum
1% ($40–$63) 100% ($48–$115) Stronger Trend ACLX
Beta / 30D Volatility
Risk Regime
1.85β · 60% Vol -0.83β · 1% Vol Lower Realized Risk ACLX
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 61.7 / 100 (BUY) Higher Composite ACLX
Trailing 12M Revenue (USD)
Operating Scale
$25M $22M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$378M ($588M Net Debt (0.47x D/E)) -$246M EBITDA ($6.95 Book/Sh · -53.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRSP +6.84 pp
CRSP: +7.23% · ACLX: +0.39%
3M Horizon ACLX +74.56 pp
CRSP: -6.7% · ACLX: +67.86%
6M Horizon ACLX +31.86 pp
CRSP: -0.23% · ACLX: +31.63%
1Y Horizon ACLX +31.86 pp
CRSP: -0.23% · ACLX: +31.63%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRSP vs ACLX. Trailing 12-month operating profitability (CRSP -2058.6% vs ACLX -3850.2%) and valuation multiples (CRSP 23.4x vs ACLX 61.7x Forward P/E) are benchmarked directly in Pillar 4 below.

CRSP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25M
Gross MarginN/A
Op. Margin-2058.6%
ROE / Fwd P/E-25.6% · 23.4x
ACLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$22M
Gross MarginN/A
Op. Margin-3850.2%
ROE / Fwd P/E-53.4% · 61.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 1.5%
IV Percentile 1st %ile
Put/Call OI Skew 9.73x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ACLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACLX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.7B market capitalization and -3850.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRSP vs ACLX Key Questions & Quantitative Answers

As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) is the stronger overall head-to-head candidate over Arcellx, Inc. (ACLX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRSP carries a Unified Composite Score of 48.6/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin), whereas ACLX carries 61.7/100 (BUY) at $115.07 (61.7x Forward P/E, -3850.2% operating margin). Composite vs. Pillar Nuance: While ACLX currently prints a higher short-term Unified Composite Score (61.7/100 BUY vs. CRSP 48.6/100 HOLD), CRSP captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-2058.6% vs. -3850.2% operating margin) and revenue trajectory (+1325.1% vs. -89.2% YoY). Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile ACLX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRSP leads the Growth & Scale pillar: CRSP posts +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin), compared with ACLX at -89.2% YoY revenue growth and +0.0% YoY earnings growth on $22M TTM revenue (N/A gross margin, -3850.2% operating margin). On trailing 12-month operating scale, CRSP generates $25M in USD-normalized revenue versus $22M for ACLX. In operating R&D and SG&A reinvestment, CRSP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACLX.

CRSP screens cheaper on headline valuation multiples. CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ACLX trades at 61.7x Forward P/E, 61.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRSP (-25.6% ROE) versus ACLX (-53.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk). By comparison, ACLX carries 1.5% implied volatility (1st %ile, Compressed (<25th %ile)), a 9.73x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.83β · 1% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.